Uremic pruritus remains an important issue in haemodiaysis patients. It has a high prevalence and is often associated with poor sleep quality, psychological disturbances, risk of infections and even death. Several interventions have been attempted with limited success thus far. Difelikefalin, a peripherally restricted and selective agonist of kappa opioid receptors might be a promising new treatment option for this condition. The results of a double-blind, placebo-controlled, phase 3 trial of the effects of difelikefalin published recently in the New England Journal of Medicine showed a significant reduction in itch intensity and improvement in the itch-related quality of life in the experimental compared to the placebo group.